Surveillance Colonoscopy Clinical Trial
Official title:
Post-polypectomy Surveillance Interval In High-risk Subjects After Screening Colonoscopy (PPSHR).
With many countries initiating population colorectal cancer (CRC) screening, including Hong Kong, more robust guidance for surveillance interval is required to maximize subject's benefit with optimal use of resources. Surveillance interval after removal of advanced adenoma at screening colonoscopy remains unclear. The current recommendation of 3-year is based on data collected before widespread implementation of population screening programs and quality metrics in colonoscopy. These high-risk subjects are those most likely to benefit from surveillance and represent the majority of the demand in surveillance colonoscopies.
Status | Recruiting |
Enrollment | 270 |
Est. completion date | December 31, 2019 |
Est. primary completion date | November 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Advanced adenoma at screening colonoscopy 2. =3 adenomas at screening colonoscopy 3. Cecal intubation at screening colonoscopy (preferably documented by images/video of the apendiceal orifice and the ileocecal valve; but not required) 4. Complete excision of all polyps at screening colonoscopy findings (after review of endoscopy reports and pathological specimens) 5. Eligible for surveillance in out-patient setting Exclusion Criteria: 1. Lack of consent 2. Incomplete screening colonoscopy 3. Incomplete endoscopic excision of polyps at screening colonoscopy 4. CRC at screening colonoscopy 5. Polyps requiring Endoscopic Submucosal Dissection at screening colonoscopy 6. Serrated polyps = 10 mm in diameter at any colorectal location or = 5 mm if located proximal to the splenic flexure on screening colonoscopy 7. Genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome) 8. Inflammatory bowel disease 9. History of surgical colon resection for any reason 10. Severe co-morbidity with reduced life expectancy (NYHA 3-4) |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Endoscopy Center, Prince of Wales Hospital | Hong Kong | |
Hong Kong | S.H. Ho Centre for Digestive Health, Prince of Wales Hospital | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Chinese University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Advanced neoplasia detection rate | Advanced neoplasia detection rate in surveillance colonoscopy among the two groups of patients | Up to 3 months | |
Secondary | CRC detection rate | CRC detection rate in surveillance colonoscopy among the two groups of patients | Up to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04640792 -
A Study to Evaluate the Safety and Efficacy of the Use of ME-APDS During Colonoscopy
|
N/A | |
Completed |
NCT01838408 -
Evaluation of Proposed EZ2go Complete Bowel Cleansing System
|
N/A |